Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
Per- and Polyfluoroalkyl Substances in Early Life Are Associated With Childhood Intestinal Inflammation: Analyses of Three Birth Cohorts.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Midya Vishal, Maroli Amith S, Picker Mellissa, Dolios Georgia, Valvi Damaskini, Nguyen Isabella, Kim Taegyu, Rendon Alexa, Chen Rosemary, Weinstein Kaitlyn, Guan Haibin, Joseph Gary, Eggers Joseph, Torres-Olascoaga Libni A, Ravisekar Rohitha, Srinath Bhargavi, Ranchadiya Romana, Andra Syam S, Achaintre David, Gennings Chris, Téllez-Rojo Martha M, Wright Robert O, Arora Manish, Rosa Maria José, Niedzwiecki Megan, Torres Joana, Alcala Cecilia S, Lane Jamil M, Eggers Shoshannah, Colombel Jean-Frederic, Peter Inga, Petrick Lauren, Agrawal Manasi
Аннотация
BACKGROUND & AIMS: Early life exposures shape intestinal and immune development and later risk of inflammatory bowel disease. Per- and polyfluoroalkyl substances, or forever chemicals, are associated with intestinal inflammation and inflammatory bowel disease. However, the impact of early life per- and polyfluoroalkyl substances exposure on later intestinal inflammation is not known.
METHODS: We conducted untargeted per- and polyfluoroalkyl substances analyses in early life samples from mother-offspring dyads across 3 cohorts. These included dried blood spots from offspring (n = 84) and cord blood (n = 93) from 2 prospective birth cohorts of mothers with and without inflammatory bowel disease in New York, New York, and maternal serum during pregnancy (n = 14) from a birth cohort in Mexico City, Mexico. Fecal calprotectin, a biomarker of intestinal inflammation, was measured longitudinally in offspring stool. Covariate-adjusted weighted quantile sum regression models were used to estimate associations between per- and polyfluoroalkyl substances and fecal calprotectin.
RESULTS: Per- and polyfluoroalkyl substances metabolites were detected across all sample types. Higher levels of per- and polyfluoroalkyl substances mixtures were associated with higher fecal calprotectin between 1 and 6 years of age in both dried blood spot and cord blood analyses (covariate-adjusted β estimates for change in log-transformed fecal calprotectin at age 6 years per decile increase in the per- and polyfluoroalkyl substances mixture was 0.44 [95% confidence interval, 0.18-0.70] and 0.69 [95% confidence interval, 0.53-0.85], respectively) Similarly, higher levels of per- and polyfluoroalkyl substances mixtures in maternal serum were associated with higher fecal calprotectin in late childhood (β, 0.19; 95% confidence interval, 0.05-0.33). Compared with mother-offspring dyads without maternal inflammatory bowel disease, those with maternal inflammatory bowel disease were more likely to have higher perfluoro-1-octane sulfonamide acetic acid and 3-perfluorohexyl-2-hydroxypropyl acrylate levels in dried blood spots and cord blood, respectively; these per- and polyfluoroalkyl substances metabolites were also the top contributors to offspring fecal calprotectin.
CONCLUSIONS: Per- and polyfluoroalkyl substances chemicals are detectable in early life samples, indicating exposure during this period of vulnerability, and are associated with higher fecal calprotectin in childhood across 3 birth cohorts.
METHODS: We conducted untargeted per- and polyfluoroalkyl substances analyses in early life samples from mother-offspring dyads across 3 cohorts. These included dried blood spots from offspring (n = 84) and cord blood (n = 93) from 2 prospective birth cohorts of mothers with and without inflammatory bowel disease in New York, New York, and maternal serum during pregnancy (n = 14) from a birth cohort in Mexico City, Mexico. Fecal calprotectin, a biomarker of intestinal inflammation, was measured longitudinally in offspring stool. Covariate-adjusted weighted quantile sum regression models were used to estimate associations between per- and polyfluoroalkyl substances and fecal calprotectin.
RESULTS: Per- and polyfluoroalkyl substances metabolites were detected across all sample types. Higher levels of per- and polyfluoroalkyl substances mixtures were associated with higher fecal calprotectin between 1 and 6 years of age in both dried blood spot and cord blood analyses (covariate-adjusted β estimates for change in log-transformed fecal calprotectin at age 6 years per decile increase in the per- and polyfluoroalkyl substances mixture was 0.44 [95% confidence interval, 0.18-0.70] and 0.69 [95% confidence interval, 0.53-0.85], respectively) Similarly, higher levels of per- and polyfluoroalkyl substances mixtures in maternal serum were associated with higher fecal calprotectin in late childhood (β, 0.19; 95% confidence interval, 0.05-0.33). Compared with mother-offspring dyads without maternal inflammatory bowel disease, those with maternal inflammatory bowel disease were more likely to have higher perfluoro-1-octane sulfonamide acetic acid and 3-perfluorohexyl-2-hydroxypropyl acrylate levels in dried blood spots and cord blood, respectively; these per- and polyfluoroalkyl substances metabolites were also the top contributors to offspring fecal calprotectin.
CONCLUSIONS: Per- and polyfluoroalkyl substances chemicals are detectable in early life samples, indicating exposure during this period of vulnerability, and are associated with higher fecal calprotectin in childhood across 3 birth cohorts.